Prevention of ischemic heart disease

Article written and reviewed by Dr Luca Moretti

Prevention of ischemic heart disease comprises all interventions capable of reducing the likelihood that coronary atherosclerosis will develop, progress, or become complicated by ischemia, infarction, heart failure, and cardiovascular death. Modern prevention does not consist simply of correcting a single risk factor: it considers cumulative lifetime exposure, the patient's absolute risk, the presence of subclinical or clinical disease, and the possibility of acting simultaneously on lipoproteins, blood pressure, smoking, metabolism, thrombosis, physical activity, and social determinants.
It is useful to distinguish primordial prevention, aimed at preventing risk factors themselves from developing; primary prevention, directed at people without clinical events but with varying risk; and secondary prevention, applied after documentation of clinical atherosclerotic disease, infarction, revascularization, or other manifestations of ASCVD. The strategies share many tools but differ in intensity, targets, and benefit-risk ratio.

Atherosclerosis is a disease that often begins decades before symptoms. Prolonged exposure to apoB-containing particles, elevated blood pressure, smoking, and metabolic abnormalities produces cumulative injury that is not fully represented by a measurement taken at age fifty. The fundamental principle is therefore lower for longer for atherogenic lipoproteins and, more generally, early and stable reduction of causal exposures.
Prevention must avoid two opposite errors: undertreating an asymptomatic high-risk individual and indiscriminately treating low-risk people with drugs whose absolute benefit is minimal. Guidelines therefore use risk models, modifiers, subclinical imaging, and conditions that automatically confer high risk.

In patients with documented ischemic heart disease, prevention does not end after PCI or bypass surgery. Revascularization corrects specific lesions or ischemic territories but does not remove other plaques or eliminate atherosclerotic biology. Permanent secondary prevention is therefore an integral part of coronary artery disease treatment.

Risk assessment and identification of subclinical disease

Preventive assessment begins with family and personal history, age, blood pressure, smoking, lipid profile, and glucose metabolism. It must also include kidney disease, inflammatory conditions, obesity, physical activity, medications, pregnancy, and reproductive history when relevant. No algorithm replaces this systematic collection.
In Europe, SCORE2 and SCORE2-OP estimate the risk of fatal and nonfatal cardiovascular events in people without ASCVD, with regional calibration. Action thresholds vary with age because absolute risk is strongly time-dependent. People with ASCVD, complicated diabetes, advanced CKD, or other high-risk conditions must not be 'downgraded' by a calculator intended for the general population.

In the United States, the 2026 dyslipidemia guidelines incorporate the PREVENT-ASCVD equations, which estimate cardiovascular risk using a contemporary model and cardiovascular-kidney-metabolic variables. The purpose of calculation is to guide intervention intensity, not to create a sharp biological boundary between the presence and absence of risk.
Risk is continuous. A threshold of 5% or 10% does not mean that atherosclerosis suddenly begins above that value. Thresholds identify levels at which the absolute benefit of therapy becomes sufficiently large to justify costs, adverse effects, and patient preferences.

A family history of premature coronary artery disease may indicate familial hypercholesterolemia, elevated Lp(a), or a high polygenic burden. Very high LDL, tendon xanthomas, or early events require specific assessment and, when appropriate, cascade screening of family members.
Lp(a) is predominantly genetically determined and remains relatively stable in adults. The 2026 ACC/AHA guidelines recommend at least one measurement in adulthood; levels ≥125 nmol/L or ≥50 mg/dL are used as indicators of increased risk, while recognizing that the relationship is continuous and the two units cannot be converted using a universal factor.

ApoB is useful when LDL-C does not adequately describe the number of atherogenic particles, as in diabetes, hypertriglyceridemia, obesity, and metabolic syndrome. Non-HDL-C instead represents the cholesterol carried by all apoB particles and can be calculated directly without fasting.
High-sensitivity C-reactive protein may identify increased inflammatory risk but does not diagnose plaque. Persistently elevated values must be interpreted after excluding infections or other causes of inflammation. Its role is that of a risk modifier in selected settings, not a universal test.

CAC measured by noncontrast CT quantifies calcified atherosclerotic burden and may reclassify risk when the decision about a statin remains uncertain. A CAC score of 0 generally identifies low short- to medium-term risk, but does not exclude noncalcified plaque, especially in young people, smokers, or those with a strong family history.
As CAC increases, risk rises and the rationale for more aggressive lipid reduction becomes stronger. The 2026 guidelines introduce progressively lower targets with a high calcific burden, treating extremely high CAC as a signal of risk approaching that of some secondary-prevention populations.

CCTA can demonstrate noncalcified plaque and total burden, but must not be used for indiscriminate screening of asymptomatic people. Preventive imaging is useful when it answers a precise clinical question and changes treatment intensity.

Lifestyle and primordial prevention

Smoking cessation is among the interventions with the greatest benefit. Cardiovascular risk declines rapidly after cessation and continues to decrease over subsequent years. Structured counseling, nicotine replacement therapy, varenicline, or other appropriate treatments increase the likelihood of success compared with generic advice alone.
Secondhand smoke also increases risk and must be avoided. Electronic cigarettes and heated products must not be presented as free of cardiovascular risk; the preventive goal remains abstinence from tobacco and nicotine, although harm-reduction strategies may have an individual role in cessation pathways.

A Mediterranean diet rich in vegetables, legumes, whole grains, nuts, fish, and olive oil, with limited processed meat, trans fats, excess saturated fat, added sugars, and sodium, has strong preventive evidence. The overall pattern matters more than emphasis on a single nutrient.
Replacing saturated fats with monounsaturated and polyunsaturated fats reduces LDL-C and risk; replacing them with refined carbohydrates does not provide the same benefit. Industrial trans fats should be minimized. Fiber intake, particularly soluble fiber, contributes to LDL reduction and improves the metabolic profile.

Regular physical activity lowers blood pressure, insulin resistance, adiposity, and cardiovascular risk. For most adults, at least 150-300 minutes per week of moderate activity or 75-150 minutes of vigorous activity is recommended, together with resistance activity and reduced sedentary time. Even increases below the target provide benefit compared with inactivity.
Insufficient or irregular sleep, obstructive sleep apnea, and circadian disorders are associated with cardiometabolic risk. Prevention should therefore include a sleep history and treatment of clinically relevant conditions, while avoiding attribution of unproven specific antiatherosclerotic efficacy to sleep interventions.

Obesity and visceral adiposity increase risk through blood pressure, diabetes, dyslipidemia, inflammation, and sleep apnea. Sustained weight reduction improves many intermediate outcomes. In appropriate patients, GLP-1 receptor agonists and related therapies can produce substantial weight loss, and some have demonstrated cardiovascular benefit in high-risk populations.
The SELECT trial showed a reduction in cardiovascular events with semaglutide 2.4 mg in adults with overweight or obesity and established cardiovascular disease without diabetes; this does not mean that every weight-loss drug prevents myocardial infarction, but documents that obesity treatment can become part of evidence-based secondary prevention.

Alcohol should not be recommended to prevent ischemic heart disease. Historical observational associations are subject to confounding, and alcohol increases other risks. People who do not drink should not start for cardiovascular reasons.
Chronic stress, depression, social isolation, and socioeconomic conditions influence adherence, behavior, and risk. Effective prevention must therefore be feasible: prescribing inaccessible therapies or programs incompatible with the patient's life reduces real-world effectiveness even when biological efficacy is high.

Atherogenic lipoproteins, LDL, apoB, Lp(a), and triglycerides

The causal role of LDL and apoB particles is supported by genetics, epidemiology, and randomized trials. Benefit depends on the absolute magnitude and duration of reduction. There is no known threshold below which further LDL reduction suddenly loses efficacy in high-risk patients.
Statins are first-line therapy. High-intensity doses are used in secondary prevention or high-risk patients when tolerated. If the target is not achieved, ezetimibe, anti-PCSK9 monoclonal antibodies, bempedoic acid, and inclisiran in specific settings provide additive reduction through different mechanisms.

The 2026 ACC/AHA guidelines recommend an LDL-C reduction of ≥50% and a target of <55 mg/dL, with non-HDL-C <85 mg/dL, in patients with ASCVD at very high risk. In patients with ASCVD not classified as very high risk, the minimum target is <70 mg/dL, with further intensification toward <55 mg/dL reasonable in many patients.
European recommendations likewise use LDL-C <55 mg/dL and a reduction of ≥50% in patients at very high risk. With recurrent events despite maximal therapy, an even lower target may be considered in selected scenarios.

Ezetimibe reduces intestinal cholesterol absorption and demonstrated benefit after ACS in IMPROVE-IT. The anti-PCSK9 antibodies evolocumab and alirocumab reduced events in FOURIER and ODYSSEY OUTCOMES. Bempedoic acid demonstrated benefit in statin-intolerant patients in CLEAR Outcomes.
Inclisiran produces a sustained reduction in PCSK9 and LDL-C with widely spaced dosing, but the strength of evidence for hard outcomes must be distinguished from that of drugs already supported by large positive cardiovascular trials. Choice must consider the magnitude of reduction needed, adherence, costs, and preferences.

So-called statin intolerance requires systematic assessment: temporal relationship, CK when indicated, interactions, hypothyroidism, and rechallenge with a different dose or agent. Many patients can tolerate a partial dose that, combined with nonstatin drugs, permits target attainment.
Elevated triglycerides often reflect an increase in triglyceride-rich lipoproteins and remnants. The first strategy is lifestyle modification, glycemic control, and a statin. In selected high-risk patients with persistent triglyceride elevation, icosapent ethyl has demonstrated event reduction; this finding cannot be generalized to all omega-3 supplements.

Elevated Lp(a) strengthens the indication to control all modifiable factors intensively. Anti-PCSK9 agents reduce it moderately. Specific antisense and siRNA therapies have produced large concentration reductions, but as of 2026, translation into definitive clinical benefit must be assessed from outcome-trial results, not inferred from lowering alone.

Blood pressure, diabetes, kidney disease, and cardiometabolic risk

Hypertension promotes atherosclerosis, remodeling, and complications. The 2025 ACC/AHA guidelines indicate a general target of <130/80 mmHg and, in patients at increased cardiovascular risk, encourage an SBP <120 mmHg when tolerated and clinically appropriate. Frailty, orthostatic hypotension, and perfusion must be considered individually.
Correct blood-pressure measurement is essential. An appropriate cuff, rest, multiple measurements, and home or ambulatory confirmation reduce errors from white-coat or masked hypertension. Prevention must not be based on a single casual measurement.

In type 2 diabetes, coronary risk depends on duration, organ damage, kidney function, lipids, and blood pressure. Glycemic control primarily reduces microvascular complications, whereas cardiovascular prevention simultaneously requires treatment of lipids and blood pressure and the use of drugs with documented cardiovascular benefit.
SGLT2 inhibitors reduce heart failure and protect the kidneys in many diabetic and cardiorenal populations. GLP-1 receptor agonists with cardiovascular evidence reduce MACE in appropriate patients and may contribute to weight loss. Choice must be guided by the cardiovascular-kidney-metabolic profile, not solely by HbA1c.

Chronic kidney disease is a powerful risk amplifier. Kidney function and albuminuria must be measured because they modify both risk estimation and treatment choice. SGLT2 inhibitors and finerenone have specific indications in diabetes and CKD that reduce renal and cardiovascular events.

Antithrombotic therapy and other pharmacological strategies

Aspirin in primary prevention must not be prescribed automatically. In contemporary trials, the modest ischemic benefit is often offset by increased bleeding. It may be considered in selected individuals with high atherosclerotic risk and low bleeding risk, but the decision is individualized.
In secondary prevention, antiplatelet therapy is instead a cornerstone. Low-dose aspirin or clopidogrel, according to context, is used long term; after ACS or PCI, a period of DAPT reduces ischemic events but increases bleeding, so duration and composition must be individualized.

In patients at very high ischemic risk and low bleeding risk, prolonged intensification strategies, such as reduced-dose ticagrelor after previous infarction or vascular-dose rivaroxaban combined with aspirin in specific populations, may reduce events. These strategies must not be applied indiscriminately.
Prevention also includes vaccination and management of comorbidities when these reduce cardiovascular precipitants. Influenza can destabilize coronary artery disease; influenza vaccination is recommended for cardiovascular patients according to preventive guidelines.

Secondary prevention, follow-up, and prognosis

After myocardial infarction, PCI, or CABG, the transition phase has extremely high preventive value. Before discharge, lipid targets, antithrombotic therapy, blood pressure, smoking, diabetes, follow-up, and referral to cardiac rehabilitation must be defined. Deferring these decisions increases the risk that they will never be implemented.
Measuring lipids after treatment initiation or modification assesses response and adherence. If the patient is far from target, intensification must occur rapidly. Waiting months or years is inconsistent with the particularly high risk of the post-ACS period.

Secondary prevention must include physical activity and supervised training when indicated. Functional capacity is a powerful prognostic marker, and improved fitness provides benefits not fully explained by changes in weight or LDL.
Low-dose colchicine reduced events in trials after infarction and in chronic coronary artery disease and is considered by European guidelines in selected patients. Kidney and liver function, tolerability, and interactions must be considered. Canakinumab demonstrated the principle of inflammation as a target but has not become routine atherosclerosis therapy.

Effective prevention requires adherence over time. Pill burden, costs, perceived adverse effects, depression, limited health literacy, and restricted access are common causes of failure. Team-based interventions, simplification, and digital follow-up may improve treatment persistence.
Prognosis must not be assessed solely as absence of myocardial infarction. Preventive goals include reducing stroke, heart failure, disability, hospitalizations, and all-cause mortality while preserving quality of life and safety. The best strategy is one the patient can maintain for years.

Prevention across the life course and high-risk populations

Cardiovascular prevention ideally begins in childhood with diet, physical activity, and avoidance of smoking, because blood pressure, adiposity, and lipid levels show tracking over time. An adolescent with elevated LDL and obesity is more likely to retain unfavorable exposures in adulthood. The primordial goal is to reduce years of exposure before a substantial anatomical burden develops.
In young adults, 10-year risk may appear low despite very high LDL, hypertension, or smoking, simply because age weighs heavily in the algorithms. In these cases, lifetime risk and the presence of severe conditions must prevent false reassurance. Familial hypercholesterolemia requires treatment regardless of a low calculated 10-year risk.

Heterozygous familial hypercholesterolemia exposes arteries to high LDL from birth. The concept of 'cholesterol-years' explains why treatment begun at age twenty potentially offers much greater protection than achieving the same LDL after a first event at age sixty. Cascade screening of relatives identifies still-asymptomatic individuals at a highly modifiable stage.
In women, modifiers related to reproductive history must be considered: preeclampsia, gestational hypertension, gestational diabetes, preterm delivery, and early menopause are associated with subsequent cardiovascular risk. These elements do not replace traditional factors but may warrant closer surveillance.

Lipid-lowering therapy during pregnancy requires specific assessment. Statins are generally discontinued in most pregnancies, although the previous absolute class contraindication has been removed in the United States. In women at extreme risk, such as some with homozygous familial hypercholesterolemia or severe ASCVD, management must be specialist-led and individualized.
In older adults, absolute risk is high, but the likelihood of frailty, polypharmacy, and interactions also increases. Prevention must distinguish an independent 78-year-old with a long life expectancy from a very frail patient with terminal illness. Treatment benefit requires time to emerge and must be consistent with goals of care.

Stage 3-4 CKD is recognized by contemporary guidelines as a condition warranting intensive lipid prevention. Risk derives not only from atherosclerosis: calcification, inflammation, anemia, and mineral abnormalities contribute. Drug choice must consider kidney function and adverse-effect risk.
HIV infection increases risk through chronic inflammation, traditional factors, and possible metabolic effects of therapy. Interactions between statins and antiretroviral drugs are clinically important. The REPRIEVE trial demonstrated a reduction in cardiovascular events with pitavastatin in people with HIV at low to moderate traditional risk.

Inflammatory diseases such as rheumatoid arthritis, lupus, and psoriasis increase risk beyond conventional factors. Control of systemic inflammation may contribute to risk reduction but does not replace treatment of LDL, blood pressure, and smoking. Some immunomodulatory drugs have specific cardiovascular effects that require knowledge of the underlying disease.
In patients with cancer, mediastinal radiotherapy and certain therapies may accelerate coronary artery disease or cause cardiac dysfunction. Prevention should begin before treatment when possible and continue during follow-up of cancer survivors, with particular attention to lipids, blood pressure, diabetes, and smoking.

Social inequalities influence exposure to ultra-processed food, spaces for physical activity, pollution, access to care, and treatment continuity. Individual prevention has limited effectiveness if it does not consider social and environmental determinants. Population interventions on tobacco, air quality, salt, and the food environment may provide benefits exceeding those of clinical medicine alone.

Advanced lipid pharmacology and management of residual risk

The choice of lipid-lowering therapy must begin with the amount of reduction needed. A high-intensity statin lowers LDL-C by an average of at least 50%, ezetimibe adds approximately 15-25%, PCSK9 antibodies often approximately 50-60%, and bempedoic acid an intermediate amount. These are average values, and the individual patient's response must be measured.
The effect of statins on events has been demonstrated in primary and secondary prevention. The relationship between LDL reduction and risk reduction is approximately proportional to the absolute reduction achieved and follow-up duration; this supports combination therapy when the target cannot be achieved with one class.

IMPROVE-IT provided important evidence for ezetimibe: further lowering LDL after ACS through a nonstatin mechanism provides additional benefit. This strengthened the concept that the causal target is lipoprotein exposure, not an exclusively pleiotropic statin effect.
FOURIER and ODYSSEY OUTCOMES demonstrated that very low LDL levels achieved with anti-PCSK9 therapy further reduce events without a safety signal sufficient to justify a mandatory lower threshold in high-risk patients. Trial duration, however, is not equivalent to decades of exposure, and clinical monitoring remains appropriate.

Bempedoic acid is activated in the liver and not in skeletal muscle, a feature that makes it useful in some patients with statin-associated muscle symptoms. It may increase uric acid and gout risk and must be used with consideration of the patient's profile.
Early combination therapy is particularly rational after ACS or in patients whose LDL is far from target. If a statin will predictably provide an insufficient reduction, waiting several visits before adding ezetimibe needlessly prolongs exposure to high levels during a high-risk period.

Residual risk may depend on Lp(a), remnants, diabetes, inflammation, thrombosis, or anatomical burden already accumulated. Achieving an LDL of 50 mg/dL does not make the patient 'risk-free.' Prevention must therefore avoid a single-factor paradigm.
Lp(a) carries apoB and apolipoprotein(a), transports oxidized phospholipids, and is associated with both ASCVD and aortic stenosis. Its measurement may explain premature events or family history in patients with apparently well-controlled LDL. It should not be repeated frequently unless conditions significantly altering its level are present.

Therapies targeting Lp(a), such as antisense agents and siRNA, represent a major development in contemporary prevention. A very large percentage reduction in the biomarker cannot be regarded as equivalent to clinical benefit until effects on events are demonstrated; this methodological principle prevents confusion of surrogate endpoints with outcomes.
ApoB is particularly informative when LDL-C and particle number are discordant. In a patient with elevated triglycerides, many particles may each carry relatively little cholesterol, producing an apparently nonelevated LDL-C despite a significant atherogenic particle number.

Non-HDL-C includes LDL, remnants, and Lp(a) and is robust in hypertriglyceridemia. The 2026 guidelines reintroduced explicit non-HDL targets alongside LDL, recognizing that atherogenic risk is not contained exclusively in classic LDL.
Nutraceutical supplements must not replace therapies with proven event benefit. Red yeast rice may contain monacolin K, which is pharmacologically similar to lovastatin but has variable dose and purity; other products have modest LDL effects and insufficient outcome evidence.

Blood pressure, thrombosis, inflammation, and integrated prevention

The benefit of blood-pressure control derives from reducing mechanical arterial stress and the risk of myocardial infarction, stroke, and heart failure. The target must not, however, be achieved at the cost of syncope or hypoperfusion. In patients with severe coronary artery disease and very low diastolic pressure, symptoms and perfusion must be monitored while therapy is intensified.
ACE inhibitors, ARBs, calcium channel blockers, thiazide-like diuretics, and other classes are selected according to comorbidities. After infarction or with ventricular dysfunction, RAAS inhibition and beta-blockade may have indications beyond blood pressure. Prevention should use drugs covering multiple objectives when appropriate.

Diabetes profoundly modifies risk. A patient with diabetes and coronary artery disease requires intensive secondary prevention regardless of an apparently good HbA1c. Blood pressure, LDL, kidney disease, and smoking may contribute more to risk than a change of a few tenths in HbA1c.
GLP-1 receptor agonists and SGLT2 inhibitors must be distinguished by outcomes. GLP-1 receptor agonists reduce MACE in several high-risk diabetic populations; SGLT2 inhibitors have a particularly robust effect on heart failure and kidney disease progression, with benefits extending beyond diabetes in specific indications.

Aspirin in primary prevention illustrates how absolute risk changes the decision. In a young low-risk person, even a relative event reduction provides very little absolute benefit while bleeding remains real. In a patient with clinical ASCVD, the balance shifts clearly in favor of antiplatelet therapy.
Secondary-prevention antithrombotic therapy must consider time since the event. Thrombotic risk is greatest in the months after ACS and PCI, when DAPT is most important. Thereafter, the benefit of intensification decreases and accumulated bleeding risk becomes increasingly relevant.

Colchicine has refocused attention on residual inflammation. The effect observed in COLCOT and LoDoCo2 does not imply that every elevated inflammatory marker should be treated with colchicine. Selection, contraindications, and the local regulatory framework must be considered.
hs-CRP may help identify a persistent inflammatory component, but the priority remains controlling LDL, smoking, blood pressure, diabetes, and weight. An inflammatory biomarker must not distract from factors with much more firmly established causal and therapeutic evidence.

PM2.5 air pollution increases cardiovascular risk at population level. Individual patients can reduce exposure on high-concentration days when possible, but effective prevention primarily requires environmental policies because the source of risk is collective.
Influenza vaccination after infarction has shown signals of event reduction in trials and is recommended in cardiovascular guidelines. Preventing respiratory infections also reduces precipitants of heart failure and plaque destabilization.

Monitoring, adherence, and measurement of preventive quality

A preventive program must be measurable. After lipid-lowering therapy is initiated or modified, the profile is reassessed to verify response and adherence. Home blood pressure, HbA1c, weight, and smoking must have explicit targets and reassessment dates.
So-called therapeutic inertia occurs when a patient remains above target for years without intensification. It may result from overestimation of adverse effects, fragmented care, or failure to appreciate risk. Reminder systems and nurse-led protocols can reduce it.

Adherence must not be judged morally. Adverse effects, costs, work shifts, depression, and dosing complexity are clinical problems to solve. A theoretically perfect therapy that is not taken has no efficacy.
The polypill approach may improve adherence by combining several cardiovascular drugs in one tablet. Post-infarction trials have shown improved adherence and reduced events in specific settings, supporting simplification strategies where available.

Follow-up must also ensure that patients do not interpret a good result as a reason to stop therapy. Low LDL while taking a statin means that treatment is working, not that the predisposition has disappeared.
Serial repetition of CAC is not an appropriate method for measuring statin efficacy. Statins may increase calcium density while stabilizing plaque; numerical score progression therefore does not amount to treatment failure.

In patients with known CCTA findings, anatomical progression should not be routinely sought in the absence of new symptoms if the result would not change management. Prevention is judged primarily by factor control and outcomes, not by repeated imaging without a clinical question.
The quality of a preventive system can be measured by the proportion of smokers supported in cessation, patients at LDL and blood-pressure targets, referral to rehabilitation, adherence, and follow-up after ACS. Well-chosen process indicators reveal gaps that an individual clinical encounter may miss.

The ultimate goal is to reduce cumulative risk over time. Prevention is not a three-month course but a strategy that must adapt to life stages, intercurrent events, and new evidence without losing continuity.

Genetics, emerging biomarkers, and personalization of prevention

Coronary risk has a diffuse hereditary component. In addition to monogenic variants in LDLR, APOB, and PCSK9, thousands of common variants contribute to polygenic risk scores. These scores may identify people at high genetic risk, but their additional clinical utility beyond traditional factors and family history varies across populations.
Transferability of polygenic scores across ancestries is an important problem because many genetic datasets overrepresent European populations. Uncritical use may amplify disparities; they therefore do not yet represent a universal preventive test.

Biomarkers such as hs-CRP, high-sensitivity troponin, and NT-proBNP may improve risk estimation in specific settings. Detectable troponin in an asymptomatic person may reflect subclinical injury and predict events, but does not identify a specific atherosclerotic mechanism and must not trigger automatic coronary angiography.
Albuminuria is a powerful marker of vascular and kidney risk, especially in diabetes. The urinary albumin-to-creatinine ratio should be measured in appropriate patients because it may modify the intensity of cardiorenal therapy.

Clonal hematopoiesis of indeterminate potential is associated with increased atherosclerotic risk, especially with certain mutations such as TET2 or JAK2. This finding has provided a link between hematopoiesis and vascular inflammation, but routine CHIP screening for coronary prevention is not yet standard.
Carotid imaging may demonstrate plaque and systemic burden, but its use for risk reclassification must follow local guidelines. Isolated intima-media thickness has less incremental value than the presence of plaque and is not recommended for universal screening.

The ankle-brachial index identifies peripheral artery disease and therefore systemic ASCVD. An abnormal ABI moves the patient toward much more intensive prevention and also requires management of limb risk.
Family history remains one of the simplest and most underused biomarkers. The age at the event and degree of kinship must be specified. A 'father with heart disease at 85' does not carry the same meaning as an infarction at 42.

Personalized preventive medicine does not mean performing as many tests as possible. It means selecting tests capable of changing the decision. If a patient with ASCVD is already a candidate for maximal lipid-lowering therapy, CAC adds no useful information to the choice.
Lp(a) measurement likewise has greatest value when it changes risk awareness, LDL-lowering intensity, or family screening. Repeating it every few months without a specific intervention rarely adds information.

After infarction and revascularization: high-intensity secondary prevention

The period immediately after ACS is characterized by a high risk of new events. Atherosclerosis is often multifocal, and the treated culprit lesion represents only part of the burden. Nonculprit plaques may progress or become complicated during subsequent months.
An early aggressive lipid strategy reduces time spent above target. In patients far from the goal, combining a statin and ezetimibe in hospital may be more rational than waiting for follow-up. Early anti-PCSK9 therapy has also been studied during ACS, producing rapid LDL reductions.

Complete revascularization in stable patients with multivessel STEMI reduces events compared with culprit-only treatment in dedicated trials, but timing and modality depend on anatomy and context. Pharmacological prevention remains necessary even after complete revascularization.
After CABG, aspirin and statins contribute to graft patency and protection of the native coronary tree. Use of DAPT after CABG depends on the indication, ACS, and graft type and must be individualized.

Diabetes control after infarction must include drugs with cardiovascular benefit and management of hypoglycemia risk. Severe hypoglycemic episodes activate the sympathetic system and may be dangerous in a patient with arrhythmias or residual ischemia.
Cardiac rehabilitation bridges the gap between prescription and real life. The program verifies that patients take their medications, stop smoking, resume activity, and understand their targets. Automatic referral before discharge increases participation.

Early follow-up must assess adverse effects and intensify treatment rapidly. If the patient reports myalgia, the goal is to find a tolerated combination, not abandon all lipid-lowering therapy. If blood pressure is low, the essential drug and the one that can be modified are identified.
Secondary prevention also includes vaccination, mental health, and social support. A patient with depression is more likely to stop therapy and remain sedentary; treating depression may therefore have an indirect effect on risk.

Communication must translate numbers into understandable decisions. Explaining that an LDL of 50 mg/dL is a goal because it reduces the risk of a second event is more effective than presenting treatment as a response to an abstract laboratory value.
After years without events, risk does not return to that of a person without ASCVD. Documented atherosclerosis is a chronic condition, and prevention must continue even when the patient is asymptomatic.

Controversies, interventions not recommended, and critical interpretation of evidence

Cardiovascular prevention is an area in which observational associations are often inappropriately transformed into recommendations. A biomarker associated with risk is not automatically a therapeutic target. HDL-C, homocysteine, and numerous supplements illustrate the need to distinguish causality from correlation.
Drugs that increase HDL-C have not demonstrated proportional event benefit when LDL and other factors are controlled. HDL function is complex, and HDL cholesterol concentration is not a pharmacological target equivalent to LDL-C.

Vitamin B supplementation to reduce homocysteine has not produced a reliable event reduction in unselected populations. Homocysteine may be a marker or participate biologically, but lowering it with vitamins is not standard coronary prevention.
Vitamin E, beta-carotene, and other antioxidants have not demonstrated cardiovascular benefit, and some have produced signals of harm. The fact that oxidative stress participates in atherogenesis does not imply that an oral antioxidant supplement usefully modifies that pathway in patients.

Over-the-counter omega-3 supplements are not equivalent to the high-purity icosapent ethyl studied in REDUCE-IT. Differences in dose, formulation, and population prevent automatic transfer of the findings.
Hormone replacement therapy must not be initiated to prevent ischemic heart disease. Its use follows menopausal indications and a specific balance of risks and benefits; randomized trials did not confirm the old observational paradigm of coronary protection.

Mass screening with exercise ECG in asymptomatic low-risk adults may generate false positives and subsequent procedures without benefit. Imaging or testing must be guided by probability and the ability of the result to change management.
Universal screening CCTA is likewise not recommended. Although it can identify early plaque, it entails costs, contrast, and incidental findings and has not demonstrated that indiscriminate screening improves outcomes compared with risk-guided prevention.

'Personalized' prevention must not become a justification for undertreating high-evidence universal interventions. A patient who smokes and has an LDL of 190 mg/dL does not need a complex genetic test before receiving smoking-cessation support and lipid-lowering therapy.
Shared decision-making is particularly important when absolute benefit is modest, as in borderline-risk primary prevention. Providing information about the number of events prevented and risks enables a more transparent choice than paternalistic recommendations.

Conversely, in very-high-risk situations, shared decision-making does not mean presenting treatment and no treatment as equivalent. The clinician must clearly explain the strength of evidence and then integrate preferences and contraindications.
Preventive medicine evolves rapidly, but every new therapy should be assessed on hard outcomes, safety, and duration. Dramatically lowering a biomarker is only the first step toward a clinical recommendation.

Practical prevention strategy: from assessment to follow-up

A practical strategy begins by identifying whether the patient is already in secondary prevention. Previous myocardial infarction, atherosclerotic stroke, peripheral artery disease, revascularization, or documented clinical coronary artery disease immediately shifts management toward intensive therapy without the need to calculate primary risk.
In primary prevention, lipids, blood pressure, smoking, diabetes, kidney function, and family history are collected and an appropriate risk model applied. Modifiers such as Lp(a), reproductive history, and inflammatory conditions are then considered and, when the decision remains uncertain, CAC.

The plan must specify targets: complete smoking cessation, blood pressure, LDL/non-HDL, weekly activity, and weight or circumference when relevant. Generic goals such as 'eat better' are difficult to monitor.
Drug selection must be built around the reduction needed. If the patient must move from an LDL of 160 to <55 mg/dL, therapy that reduces it by 30% on average is predictably insufficient, and combination therapy should be planned from the outset.

Response is assessed after 4-12 weeks, sooner if risk is very high. Failure to achieve the target requires distinguishing nonadherence, insufficient biological response, and intolerance. Each problem has a different solution.
Annual or six-monthly follow-up must not be limited to renewing prescriptions. New events, medications, smoking, activity, weight, blood pressure, kidney function, and diabetes must be reassessed. Risk changes with age and comorbidities.

After a clinical event, the plan is recalibrated. A patient previously in primary prevention moves into secondary prevention and targets become more aggressive. The same values that were acceptable before may no longer be so.
Population and individual prevention are complementary. Reducing salt in foods, prohibiting smoking in public spaces, and lowering PM2.5 reduce risk for millions of people, while intensive pharmacotherapy concentrates benefit in high-risk individuals.

Success is measured over the long term through reduced myocardial infarction, stroke, heart failure, and death and preservation of years of healthy life; this is why starting early is more important than waiting for the first symptom.

Diet, physical activity, sleep, tobacco, and environmental determinants

Effective prevention does not derive from isolated correction of a single biomarker, but from simultaneously reducing exposures that cause atherosclerosis throughout life. The best-supported dietary patterns prioritize vegetables, legumes, fruit, whole grains, nuts, fish, and unsaturated fats while limiting trans fats, excess saturated fat, sodium, added sugars, and ultra-processed foods. The quality of substitution is essential: replacing saturated fats with monounsaturated or polyunsaturated fats has different effects from replacing them with refined carbohydrates.
The Mediterranean pattern is supported by trials and prospective studies, but must not be reduced to the use of olive oil. It comprises the overall dietary structure, a high proportion of plant foods, fewer industrial products, and consumption of favorable fat sources. The prescription must be adapted to diabetes, CKD, obesity, cultural preferences, and economic sustainability, because a theoretically optimal but unsustainable diet does not modify cumulative exposure.

Physical activity reduces cardiovascular risk through blood pressure, insulin sensitivity, body composition, endothelial function, and cardiorespiratory capacity. For most adults, at least 150 minutes per week of moderate aerobic activity or 75 minutes of vigorous activity is recommended, together with resistance exercise and reduced sedentary time. Benefits are evident even below these thresholds and increase progressively when moving from inactivity to moderate levels of movement.
Cardiorespiratory fitness is a powerful prognostic marker. Two people reporting the same activity time may have very different capacities, so exercise testing or CPET may improve prescription precision in high-risk patients. The aim is not to turn everyone into an athlete, but to maintain a habitual workload sufficient to preserve functional capacity and a favorable metabolism.

Tobacco cessation produces a substantial risk reduction, but nicotine dependence must be treated as a chronic relapsing condition. Counseling, nicotine replacement therapy, varenicline, or bupropion may increase the likelihood of success in appropriate patients. Secondhand exposure and combustible products other than cigarettes also contribute to risk. Reducing the number of cigarettes is not equivalent to eliminating exposure.
Electronic cigarettes may reduce exposure to some combustion products when they completely replace smoking, but are not free of cardiovascular effects and must not be interpreted as a zero-risk condition. The health goal remains abstinence from tobacco and, where possible, freedom from nicotine dependence. Dual use may maintain a substantial proportion of toxic exposure.

Insufficient sleep, obstructive sleep apnea, night work, and circadian irregularity are associated with hypertension, metabolic abnormalities, and cardiovascular risk. Treating sleep apnea improves symptoms and some physiological parameters, but its effect on cardiovascular events depends on severity, adherence, and population. Sleep assessment is particularly relevant in patients with obesity, resistant hypertension, or daytime sleepiness.
Air pollution and fine particulate matter contribute to risk through oxidative stress, inflammation, and autonomic and vascular dysfunction. Individual exposure is partly determined by environmental policies and housing conditions, so cardiovascular prevention also has a public-health dimension. Individual recommendations can reduce very high exposures but do not replace collective environmental interventions.

Obesity, diabetes, cardiometabolic drugs, and integrated prevention

Obesity is not merely an intermediary between diet and diabetes. Visceral adiposity modifies inflammation, blood pressure, lipoprotein metabolism, endothelial function, and thrombotic risk. Waist circumference may provide additional information beyond BMI, particularly in people with an intermediate BMI. Prevention must therefore consider fat distribution and weight trajectory, not merely a numerical threshold.
A weight reduction of 5-10% may improve blood pressure, triglycerides, and glycemic control, while greater losses may produce deeper metabolic changes. In patients with obesity and established cardiovascular disease, semaglutide 2.4 mg reduced major cardiovascular events in SELECT even without diabetes; this finding supports obesity treatment as a direct component of secondary prevention in selected patients.

In type 2 diabetes, drug selection must integrate HbA1c and organ protection. SGLT2 inhibitors primarily reduce heart failure and kidney disease progression, whereas several GLP-1 receptor agonists have demonstrated reductions in atherosclerotic events. The benefit of these classes does not depend exclusively on glucose lowering and may justify their use in patients with ASCVD or high risk even when HbA1c control is relatively good.
Chronic kidney disease amplifies risk and modifies both prevention and treatment safety. Reduced eGFR and albuminuria must be considered together. SGLT2 inhibitors and, in subgroups with diabetes, nonsteroidal mineralocorticoid receptor antagonists may reduce kidney disease progression and cardiovascular events. Coronary prevention in CKD also requires intensive blood-pressure and lipid control compatible with kidney function.

Blood pressure must be measured correctly using an appropriate cuff, rest, and home or ambulatory confirmation when necessary. The 2025 United States recommendations generally pursue values below 130/80 mmHg and encourage lower systolic pressure in many adults at increased risk when well tolerated. In patients with coronary artery disease, symptomatic hypotension and low diastolic pressure require individualization.
The polypill concept aims to reduce therapeutic inertia and improve adherence by combining preventive drugs in one formulation. Secondary-prevention studies have shown improved adherence and, in some settings, fewer events. The organizational advantage must be balanced against the need to titrate individual components and the availability of appropriate combinations.

Prevention must consider drug interactions and treatment burden. A patient taking ten drugs on complex schedules may have lower adherence than one following a simplified strategy. Deprescribing drugs without benefit, synchronizing dosing, and using fixed combinations may increase actual exposure to therapies that modify prognosis.

Lipoproteins, contemporary targets, and strategies beyond statins

The relationship between apoB-containing particles and atherosclerosis is causal and cumulative. LDL-C remains the principal treatment parameter, but apoB and non-HDL-C may better describe the total number of atherogenic particles when triglycerides, diabetes, or insulin resistance produce discordance. The 2026 guidelines more explicitly incorporate these biomarkers into risk personalization.
A high-intensity statin remains the foundation of secondary prevention. If the expected reduction will not achieve the target, early addition of ezetimibe avoids months or years of exposure to above-target LDL. In very-high-risk patients, anti-PCSK9 antibodies provide a further marked reduction with demonstrated event benefit. Choice must depend on distance from target, absolute risk, and adherence, not on a rigidly slow sequence.

Bempedoic acid has demonstrated cardiovascular benefit in statin-intolerant patients and may be combined with ezetimibe. Inclisiran produces sustained LDL reduction through PCSK9 silencing and may improve adherence through widely spaced administration, but the strength of cardiovascular-outcome evidence must be distinguished from that of monoclonal antibodies until dedicated outcome trials are completed.
Lp(a) should be measured at least once in adulthood according to contemporary recommendations. Its level is predominantly genetic and relatively stable, so repeated measurements are not routinely needed. Elevated values identify residual risk and justify more aggressive control of LDL and other factors, although selective anti-Lp(a) therapies do not yet, as of the date of this monograph, have definitive evidence of event reduction.

Elevated triglycerides require distinction between pancreatitis risk and atherosclerotic risk. In the moderately elevated range, the main problem is often an increased number of cholesterol-rich remnants. The foundation of therapy remains control of weight, diabetes, alcohol, and apoB lipoproteins. Icosapent ethyl demonstrated event reduction in a selected statin-treated population, a finding that cannot be generalized to every omega-3 formulation.
CAC measurement may reclassify risk in primary prevention when the decision about lipid-lowering therapy remains uncertain. High CAC indicates cumulative atherosclerotic burden and strengthens the indication for an intensive strategy. A CAC score of zero lowers short-term risk in many people but does not exclude noncalcified plaque, especially in young people, smokers, patients with diabetes, or those with a strong genetic predisposition.

Secondary prevention does not require a new score to demonstrate that the patient is at high risk. After myocardial infarction, atherosclerotic stroke, or clinically documented coronary artery disease, the priority is to reduce residual risk through treatment targets and adherence. Scores may help quantify relative risk intensity but must not be used to downgrade indications for treatments already supported by the presence of ASCVD.

Implementation, inequalities, and prevention as a longitudinal process

One of the main causes of preventable events is failure to achieve targets despite the availability of effective therapies. Clinical inertia includes delayed drug intensification, excessively spaced assessments, and failure to verify adherence. An above-target LDL or blood-pressure value must trigger a defined action and repeat measurement within an interval consistent with the treatment change.
Adherence must be assessed without automatically assigning responsibility to the patient. Costs, adverse effects, regimen complexity, health literacy, and beliefs about drugs can be modified. A specific conversation about which doses are actually taken is more useful than a generic question such as 'do you take your medication regularly?'

Socioeconomic inequalities influence exposure to smoking, diet, physical activity, pollution, and access to drugs. Individual prevention that ignores these determinants risks widening differences. Reminder systems, simplified prescriptions, lower costs, and local access to rehabilitation can transform a theoretical recommendation into a real reduction in risk.
Prevention must be measured using process and outcome indicators: the proportion of patients at LDL and blood-pressure targets, smoking cessation, rehabilitation participation, adherence, appropriate vaccination, and diabetes control. Prescription alone does not demonstrate system effectiveness. A high-quality program must verify whether biological exposure has actually decreased.

Cardiovascular risk changes over time. New CKD, diabetes, early menopause, inflammatory disease, or a previously known increase in Lp(a) may modify the strategy. Conversely, improved weight and blood pressure do not make previous atherosclerosis irrelevant. Prevention is therefore a longitudinal process integrating cumulative history and current status.
Precision medicine does not consist of replacing established therapies with complex panels. The greatest benefit often derives from identifying which determinant predominates in the individual patient and treating it with sufficient intensity: very high LDL, smoking, hypertension, diabetes, obesity, CKD, or Lp(a). Genomics and biomarkers may refine estimation but must not delay control of already evident causal factors.

The ideal result of prevention is to shift the event curve toward older ages or prevent events altogether; this requires beginning before plaque burden is high and maintaining control for decades. Temporary lowering of LDL or blood pressure for a few months does not compensate for years of subsequent exposure. The duration of prevention is therefore an integral part of the therapeutic dose.